One-third of COVID survivors diagnosed with mental health conditions

Contracting COVID-19 is “robustly associated” with an increased risk of developing mental health and neurological conditions in the six months after a diagnosis, a study suggests.

Researchers at the University of Oxford looked at the TriNetX electronic 2020 health records of more than 230,000 COVID-19 patients, mostly from the US.

The study, published in The Lancet Psychiatry journal and said to be the largest of its kind to date, estimated that 34 per cent of COVID-19 survivors were diagnosed with a neurological or psychiatric condition within six months of being infected.

For 13 per cent of people it was their first recorded neurological or psychiatric diagnosis, researchers found.

The findings also suggested that the incidence of such conditions rose with the severity of a coronavirus case, with a neurological or psychiatric diagnosis occurring in 39 per cent of those who were admitted to hospital, 46 per cent of those in intensive care, and 62 per cent in those who had encephalopathy – described as “delirium and other altered mental states” – during their COVID-19 infection.

Read more about coronavirus:

• Coronavirus vaccine: Is it safe?
• Should we infect people with COVID-19 for vaccine research?
• COVID-19 Vaccine UK: Everything you need to know about the coronavirus jabs.

When comparing the data with a control group and taking into account underlying health characteristics such as age, sex, ethnicity, and existing health conditions, researchers also found that overall there was a 44 per cent greater risk of neurological and mental health diagnoses after COVID-19 than after flu, and a 16 per cent greater risk after COVID-19 than with other respiratory tract infections such as pneumonia.

Given the scale of the coronavirus pandemic and chronic nature of some neurological and psychiatric diagnoses, the study’s authors concluded that “substantial effects on health and social care systems are likely to occur”.

They argued that “urgent” research was needed to understand how and why such disorders occur and how they can be treated.

• Subscribe to the Science Focus Podcast on these services: Acast, iTunes, Stitcher, RSS, Overcast

“These are real-world data from a large number of patients. They confirm the high rates of psychiatric diagnoses after COVID-19, and show that serious disorders affecting the nervous system (such as stroke and dementia) occur too,” said lead researcher Prof Paul Harrison of the University of Oxford.

“While the latter are much rarer, they are significant, especially in those who had severe COVID-19.

“Although the individual risks for most disorders are small, the effect across the whole population may be substantial for health and social care systems due to the scale of the pandemic and that many of these conditions are chronic.

“As a result, health care systems need to be resourced to deal with the anticipated need, both within primary and secondary care services.”

Read the latest coronavirus news:

• Vaccination alone is not enough to contain COVID-19
• COVID-19: Reinfection ‘more common in over 65s’

For the peer-reviewed observational study, researchers looked at the incidence of 14 neurological and mental health disorders among 236,379 patients over the age of 10 who were infected with COVID-19 on or after 20 January 2020 and who were still alive on 13 December that year.

This group was compared with 105,579 patients diagnosed with influenza and 236,038 patients diagnosed with any respiratory tract infection, including influenza.

In the COVID-19 group, researchers found anxiety disorders occurred among 17 per cent of all patients, while 14 per cent developed mood disorders, 7 per cent had substance misuse disorders and 5 per cent insomnia.

Meanwhile, the incidence of neurological conditions appeared lower, with 0.6 per cent having a brain haemorrhage, 2.1 per cent ischaemic stroke and 0.7 per cent dementia.

Report co-author Dr Max Taquet, National Institute for Health Research academic clinical fellow in psychiatry at the University of Oxford, said that while a diagnosis such as psychosis or dementia was less likely to occur in all patients with COVID-19, the rate “increased quite dramatically” with a more severe COVID-19 illness.

He highlighted that 7 per cent of patients with encephalopathy were found to have a psychosis diagnosis and 5 per cent had dementia, compared to 1.4 per cent and 0.7 per cent of all patients with COVID-19 respectively.

Dr Taquet said another “concerning” finding was that 2 per cent of patients with COVID-19 went on to have an ischaemic stroke within six months – where a blood clot affects the brain – which increased to 9 per cent with encephalopathy.

Overall the authors concluded that COVID-19 does lead to a greater risk of neurological and psychiatric disorders when compared with flu and other respiratory tract infections, but there was no clear evidence this was the case for some conditions such as Parkinson's and Guillain-Barré syndrome.

“Our view is that a lot of the mental health consequences of COVID are… to do with the stress of knowing that one has had COVID and all the implications that go with that, rather than it being a direct effect, for example, of the virus on the brain, or the immune response to the virus on the brain,” said Harrison.

The researchers also warn that although it was known coronavirus can access the brain, the evidence it affects neurons is quite low.

And that there is a need to be “careful” over whether conditions such as dementia and strokes were a direct consequence of the virus or whether the effects of being ill on clotting, for example, on the immune system can have an effect.

They also noted that their study was limited by the unknown completeness and accuracy of the electronic health records and that the results may not apply to people who had COVID-19 but were not diagnosed with the illness.

The severity of the neurological and psychiatric disorders was also not known, nor whether patients recovered and what happened to them after six months.